Blog
SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 /EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA., to be held April 8-13, 2022. Two...
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on...
Medidata, a Dassault Systèmes company, today announced that Translational Drug Development (TD2), a precision oncology contract research...
Key Partnership Will Connect Patients with Precision Oncology Clinical Trials and Novel Therapies, Accelerating Access to Promising Treatments...
The Companies Plan to Focus On Voltron’s VaxCelerate Vaccine Platform’s Effectiveness and Utility in a Variety of Tumor Settings Laidlaw Venture...